Tepmetko 225mg Tablet

About

Tepmetko 225mg Tablet contains tepotinib, an oral MET kinase inhibitor specifically indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. This precision oncology drug functions by selectively inhibiting the MET receptor tyrosine kinase, a protein that, when overactivated or mutated, drives uncontrolled cell growth, survival, and metastasis in various cancers. By blocking the aberrant MET signaling pathway, tepotinib effectively reduces tumor cell proliferation, inhibits angiogenesis (the formation of new blood vessels that feed tumors), and promotes programmed cell death (apoptosis) in cancer cells. Its targeted action makes it particularly effective in patients whose tumors exhibit these specific genetic mutations, representing a significant advancement in personalized cancer therapy. The oral administration offers a convenient treatment option for eligible patients.

Uses

• Metastatic non-small cell lung cancer (NSCLC)
• NSCLC with MET exon 14 skipping alterations
• Patients who have progressed on prior therapy
• First-line treatment for specific NSCLC patients

Directions For Use

Take orally once daily with food. Swallow the tablet whole; do not crush, chew, or split.

Benefits

• Targets specific MET alterations in NSCLC
• Improves progression-free survival
• Offers an oral treatment option
• Effective in previously treated patients
• May reduce tumor size
• Potential for improved overall survival

Side Effects

• Peripheral edema
• Nausea
• Diarrhea
• Fatigue
• Increased creatinine
• Hypoalbuminemia
• Dyspnea
• Abdominal pain
• Vomiting
• Rash
• Constipation
• Muscle spasms

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it may increase the risk of liver-related side effects.
• Pregnancy - Tepmetko can cause fetal harm; effective contraception is required during treatment and for a period after the last dose.
• Breastfeeding - It is not recommended during breastfeeding due to potential harm to the infant; discontinue breastfeeding during treatment.
• Liver - Use with caution in patients with hepatic impairment; liver function tests should be monitored regularly.
• Kidney - Dose adjustments may be necessary for severe renal impairment; monitor kidney function closely.
• Lung - Patients should be monitored for new or worsening interstitial lung disease (ILD) symptoms; discontinue if ILD is confirmed.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.